Evidence map›Paper›PMID 39542988›Full record

ReviewFrontiers of medicine2024

Novel perspectives on the link between obesity and cancer risk: from mechanisms to clinical implications.

Xiaoye Shi, Aimin Jiang, Zhengang Qiu, Anqi Lin, Zaoqu Liu, Lingxuan Zhu, Weiming Mou, Quan Cheng, Jian Zhang, Kai Miao and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Frontiers of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaoye Shi *Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China.
Aimin Jiang *Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, 200433, China.
Zhengang Qiu *Department of Neurology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China.
Anqi Lin *Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China.
Zaoqu LiuKey Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, 102206, China.
Lingxuan ZhuDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China.
Weiming MouDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China.
Quan ChengDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, 410008, China. chengquan@csu.edu.cn.
Jian ZhangDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China. zhangjian@i.smu.edu.cn.
Kai MiaoCancer Centre, Faculty of Health Sciences, University of Macau, Macao SAR, 999078, China. kaimiao@um.edu.mo.
Peng LuoDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China. luopeng@smu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Existing epidemiologic and clinical studies have demonstrated that obesity is associated with the risk of a variety of cancers. In recent years, an increasing number of experimental and clinical studies have unraveled the complex relationship between obesity and cancer risk and the underlying mechanisms. Obesity-induced abnormalities in immunity and biochemical metabolism, including chronic inflammation, hormonal disorders, dysregulation of adipokines, and microbial dysbiosis, may be important contributors to cancer development and progression. These contributors play different roles in cancer development and progression at different sites. Lifestyle changes, weight loss medications, and bariatric surgery are key approaches for weight-centered, obesity-related cancer prevention. Treatment of obesity-related inflammation and hormonal or metabolic dysregulation with medications has also shown promise in preventing obesity-related cancers. In this review, we summarize the mechanisms through which obesity affects the risk of cancer at different sites and explore intervention strategies for the prevention of obesity-associated cancers, concluding with unresolved questions and future directions regarding the link between obesity and cancer. The aim is to provide valuable theoretical foundations and insights for the in-depth exploration of the complex relationship between obesity and cancer risk and its clinical applications.

Indexed as

NeoplasmsObesityAdipokinesBariatric SurgeryHumansInflammationRisk FactorsAdipokinescancer preventioncancer riskcarcinogenesisobesityobesity-associated cancers

Identifiers

PMID39542988

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.